Engage Bio Analysis: $125K Raised
What is Engage Bio?
Engage Bio develops Tethosomes, a non-viral DNA platform for effective, durable, and scalable genetic medicine, addressing challenges in gene therapy.
Employees
5
Founded
2021
Product Features & Capabilities
- Tethosomes, non-viral DNA delivery platform, highly potent (over 100x expression), non-immunogenic, redosable (months to years of expression), ready to scale (low manufacturing complexity).
How much Engage Bio raised
Seed - $125K
March 29, 2022Lead Investor: Y Combinator, WorldQuant Ventures, and 2 others.
Who are the founders of Engage Bio
WO
Will Olsen
CEO
Market Focus
Engage Bio primarily focuses on the biotechnology industry, specifically in the development of genetic therapies using a new class of non-viral DNA medicines known as Tethosomes.
Business Model
Revenue generated through partnerships and collaborations in gene therapy and oncology.
Investors
- Y Combinator
- WorldQuant Ventures
- Unpopular Ventures
- 1 other investor (not specified)
Competitors Overview
Engage Bio operates in the market of non-viral DNA delivery systems, specifically focusing on Tethosomes for enhancing genetic medicines. Its main competitors include:
- Thermo Fisher Scientific: They offer a range of non-viral delivery systems, including the Invitrogen Vivofectamine, which is
See something that needs updating? Suggest edits to this profile.